CN1658907A - Radiopharmaceutical formulations - Google Patents
Radiopharmaceutical formulations Download PDFInfo
- Publication number
- CN1658907A CN1658907A CN03812954XA CN03812954A CN1658907A CN 1658907 A CN1658907 A CN 1658907A CN 03812954X A CN03812954X A CN 03812954XA CN 03812954 A CN03812954 A CN 03812954A CN 1658907 A CN1658907 A CN 1658907A
- Authority
- CN
- China
- Prior art keywords
- compositions
- chemical compound
- general formula
- diluent
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
Abstract
Radiopharmaceutical compounds are disclosed having a radionuclide chelating moiety and a targeting ligand, and optionally a linker. Formulations of compositions useful for making the radiopharmaceutical compounds contain a chelating ligand, a reducing agent, an exchange ligand and a stabilizer.
Description
This is the part continuation application of the U. S. application submitted on May 3rd, 2002 number 60/377,454.
Invention field
The present invention relates to contain the radiopharmaceuticals preparation of radionuclide chelators.
Background of invention
The targeting radiopharmaceutical can be resolved the image with diagnostic significance, perhaps by with body in position selective binding or location, carry a kind of therapeutic radiation isotope to the target area.For different diagnosis and therapeutic use, successfully used to some extent with the metal radionuclide in conjunction with and the chelating agen that is connected with targeted molecular.These chelating agen contain a zone usually, have wherein mixed 4 or more donor atom, form 5 yuan or 6 yuan of rings, and it is suitable for combining with the radionuclide high-affinity.The typical metal radionuclide that the diagnostic imaging agent is used comprises different chlorides, oxide or nitride form
99mTc,
64Cu,
67Cu,
97Ru,
109Pd,
198Au,
199Au,
111In.The typical metal radionuclide that is used for the radiotherapy purposes comprises different chlorides, oxide or nitride form
186Re,
188Re,
111In,
166Ho,
105Rh,
149Pm,
153Sm,
177Lu,
90Y,
203Pb,
212Pb and
212Bi.Polytype molecule comprises polyclone and monoclonal antibody and fragment thereof, protein and peptide as targeted molecular, particularly can with those (being commonly referred to " receptors bind part ") of cell surface receptor specific bond.When labelling during based on peptide and proteinic targeting agent, chelating agen also is based on peptide ideally, can utilize the peptide synthetic technology to synthesize chelating agen-targeted molecular conjugate like this.For example, U.S. Patent number 5,662,885; 5,780,006; With 5,976,495 (all are incorporated by reference in this text and examine) disclose and the bonded chelating agen of metal radionuclide, they can with the targeting agent coupling of the body part that can be positioned to have diagnosis and treatment meaning, be structurally to design to present a kind of N
3The peptide analogues of S configuration, this configuration can be in conjunction with for example
99mTc and
186/188The oxygenate of Re, two oxygenates and nitrilo-(nitrido) ion.And the peptide core of the isotope of chelating Tc and other diagnosis and radiotherapy nucleic is known; Great majority work all concentrates on uses NH
2The deutero-peptide of the natural amino acid of CHRCOOH form.
Although diagnostic imaging has been obtained many progress, in this field, still often run into several obstacles.A key issue is the research and development that can be used for preparing the radiopharmaceutic preparation of targeting.A problem that often runs into is that in the radiopharmaceutic reaction of preparation targeting, many preparations need the targeting cheland of high concentration to guarantee the complex of the hope of high yield.These preparations produce radiopharmaceutical goods, wherein contain remarkable content not with " dissociating " targeting cheland of radioactive metal chelating.For many purposes, this " dissociating " part is undesirable; Therefore, before further using, must utilize chromatographic technique,, it be separated with the part of labelling as high pressure liquid chromatography (HPLC).For example, when the targeted molecular that is connected with chelating agen is an agonist, and with the target receptors bind after when showing biological activity, this separation is normally necessary.This biological activity is undesirable in diagnostic compounds, also may be undesirable in the treatment chemical compound.In addition, with the receptors bind part of radionuclide complexation can target receptor place with a kind of part competition of radionuclide complexation, cause radionuclide complex targeting relatively poor, diagnosis or treatment feature are less.
Structure targeting radiopharmaceutical as shown in Figure 1 is an example.The receptors bind part (or targeting cheland) that is used for preparing the not complexation of this complex contains a tripeptides N
3S chelating agen [(N-(Me
2)-Gly-Ser-Cys (Acm)], it and Tc (V) O form complex, have lost acetamidomethyl (Acm) protecting group in this process.This chelating agen sequence is by a Gly-aminovaleric acid joint and a kind of octapeptide targeted molecular pGlu-Trp-Ala-Val-Gly-His-Leu-Met-NH that derives from bombesin
2N end connect.This part and by the Tc complex that it forms all be known can high-affinity in conjunction with the agonist of gastrin releasing peptide (GRP) receptor.Referring to, for example: U.S. Patent number 6,200,546 is incorporated by reference in this text and examines.The clinical research of carrying out with this chemical compound, as people (European Journal ofNuclear Medicine, Vol.27, No.11 such as Van de Wiele, 2000 p.1694 (be incorporated by reference in this text and examine) described, with below contain 4 bottles the prototype test kit carry out.In 2 bottles that respectively contain 100 μ g parts, respectively add 0.1mL stannous chloride (2mM), 0.1mL gluconic acid sodium salt (60mM), the 1850-2035MBq (50-55mCi) in 0.3mL 0.9% sodium chloride solution
99mTcO
4-and 0.5mL sodium chloride.In boiling water bath after 35 minutes, the reactant mixture that merges is expelled in the HPLC system, purification separates the peptide and the unlabelled peptide of labelling, carries out last sterilization subsequently.This radiates synthetic total output is～30%, the radiochemical purity behind the purification＞90%.The chemical compound of purification can only be stored the longest 2 hours down at 4 ℃.Although this method can be used for the potential clinical application of proof chemical compound when beginning, but it can not obtain as commodity, because it uses the freezing test kit of 4 bottles, before injection, need to remove excessive part, can't not provide sterile product by final sterilization with preparation HPLC (being the instrument that nuclear medicine unit does not generally have).In addition, its use＞100mCi
99mTcO
4 -Form a patient dose, need to use 2 hours or less than 2 hours generator eluant, the product of purification can only use 2 hours after separation.
Very advantageously be to produce a kind of preparation, it is used to prepare this and targeting radiopharmaceutical other receptors bind, and this medicine does not need the HPLC purification to get final product clinical use (for example direct injection).The invention solves some other problem in these needs and this area.
Summary of the invention
The present invention has characterized radiopharmaceuticals preparation useful in diagnostic imaging and/or radiotherapy.On the one hand, the present invention has characterized the radiopharmaceuticals preparation that contains the targeting cheland, and these parts have the structure of general formula I:
R wherein
1Be H, or linear or ramose, saturated or undersaturated C1-4 alkyl chain, it is randomly interrupted by the hetero atom that one or two is selected from N, O and S; Randomly replaced by at least one group that is selected from halogen, hydroxyl, amino, carboxyl, C1-4 alkyl, aryl and C (O) Z;
R
2Be R
1A substituent group of definition; Perhaps
R
1And R
2Can constitute the saturated or unsaturated heterocycle of a 5-8 unit together, it is randomly replaced by the group that at least one is selected from halogen, hydroxyl, amino, carboxyl, C1-4 alkyl, aryl and C (O) Z;
R
3Be
-H,-CH
2OH or-tert-butyl group;
L chooses wantonly, and is a connection base;
Z is a targeted molecular.
In preferred embodiments, said preparation contains R
1And R
2It all is the compositions of methyl.In a preferred embodiment, R
1And R
2All be methyl, Z is the bombesin analog, most preferably is the bombesin analog as agonist, and as U.S. Patent number 6,200,546 is disclosed, is incorporated by reference in this text and examines.
With to be used to prepare the radiopharmaceutic multiple existing compositions of targeting different, radiopharmaceuticals preparation of the present invention uses a small amount of chelating agen/targeted molecular conjugate (for example chemical compound of general formula I).In fact, in a preferred embodiment, radiopharmaceuticals preparation of the present invention is provided, and it contains the targeting cheland of the about 10 μ g general formulas 1 of 2 μ g-of having an appointment, and has therefore reduced and has used the danger that the biological example bioactive peptide produces undesirable biological activity or physiological effect.
Radiopharmaceuticals preparation of the present invention also contains composition described in detail herein (for example Reducing agent, exchange part, stabilizing agent, solubilizing agent, diluent etc.).In a preferred embodiment, preparation inclusion compound 1 of the present invention, SnCl
22H
2O, gluconic acid (sodium salt), gentisic acid (sodium salt), ethanol and optional hydroxypropyl-gamma-cyclodextrin, or the acceptable salt of its pharmacy.
The present invention also comprises and is used to prepare the radiopharmaceutic test kit of the targeting that contains radiopharmaceuticals preparation of the present invention.Preferred test kit is included in targeting cheland, Reducing agent, exchange part, stabilizing agent and any solubilizing agent of the not complexation in one or more bottles, and contains diluent in a different bottle.A particularly preferred test kit of the present invention comprises two bottles.First bottle contains: chemical compound 1, SnCl
22H
2O, gluconic acid (sodium salt), gentisic acid (sodium salt) and hydroxypropyl-gamma-cyclodextrin randomly.Second bottle contains ethanol and randomly water and/or normal saline.
In a preferred embodiment, the radiochemical purity value (RCP) of radiopharmaceuticals preparation of the present invention in back 15 minutes of reconstruction more than or equal to 90%.In a further preferred embodiment, the radiochemical purity value of radiopharmaceuticals preparation of the present invention back 6 hours of reconstruction more than or equal to 90%.Radiopharmaceutical by formulation preparation of the present invention can be without any purification directly to patient infusion.In addition, these radiopharmaceutical also can at room temperature prepare.
The accompanying drawing summary
Fig. 1 shows chemical compound 1
99mThe chemical constitution of Tc complex, chemical compound 1 are a kind of preferred targeting chelands that uses in the preparation of the present invention.
Detailed Description Of The Invention
Radiopharmaceuticals preparation of the present invention had significant advantage than former preparation. These preparations contain than the significantly less target chelating agent of existing preparation. In fact, the every mL diluent of preparation of the present invention contains less than 10 μ g target chelating agents. Preferably, the every mL diluent of a kind of radiopharmaceuticals preparation of the present invention contains less than about 5 μ g target chelating agents. Most preferably, the every mL diluent of a kind of radiopharmaceuticals preparation of the present invention contains the 4 μ g target chelating agents of having an appointment, and always rebuilding volume is the about 1mL of about 0.5mL-, is most preferably 1.0mL. Particularly, the invention provides the radiopharmaceuticals preparation that does not need any purifying to prepare and the experimenter is used. In addition, radiopharmaceuticals preparation of the present invention was rear about 15 minutes of preparation (namely rebuilding), and its radiochemical purity (RCP) is more than or equal to 90%. The most preferred radiopharmaceuticals preparation of the present invention the preparation about 6 hours after RCP more than or equal to about 90%.
The diluent that is used for rebuilding radiopharmaceuticals preparation of the present invention can be any combination of water, physiological saline and/or ethanol. Preferably, this diluent is the mixture of water, physiological saline and ethanol, and wherein the percentage of ethanol is about 40% (v/v) of about 20%-, most preferably about 30%. The pH of the preparation after the reconstruction is 2.8-4.0, most preferably is about pH3.0.
Radiopharmaceutical of the present invention can by with a kind of reducing agent reaction preparation, this reducing agent radionuclide (state of oxidation) can be reduced to can with the reducing condition of part (such as inferior Xi Yuan, sodium borohydride, Cu (I) salt, FAS etc.) coordination. Preferred reducing agent is a kind of tin salt, such as stannous chloride, stannous fluoride, stannous tartrate etc. Stannous chloride is (as SnCl2·2H
2O) be most preferred. The concentration of reducing agent is the about 60 μ g/mL of about 20 μ g/mL-, most preferably about 40 μ g/mL.
Preparation of the present invention has preferably closed one or more stabilizing agents, is selected from: maltose, ascorbic acid, gentianic acid or the acceptable salt of these sour pharmacy. The gentianic acid sodium salt is most preferred. The concentration of this reagent is preferably about the about 25mg/mL of 10mg/mL-, is most preferably 20mg/mL.
Preferably contain the exchange part in the preparation of the present invention, to help the Tc of the stable state of oxidation of reducing, until it and the target cheland chelating of wishing. These the exchange parts can comprise, for example: gentianic acid, glucose acid group or glucoheptose acid group, or the acceptable salt of the pharmacy of these compounds. Gluconic acid sodium salt is most preferred. The concentration of exchange part is the about 3mg/mL of about 1mg/mL-, is most preferably 1.3mg/mL.
Randomly contain a kind of detergent in the preparation of the present invention, to help to improve the yield that from bottle, reclaims radioactive product. These detergents can comprise nonionic, cation, anion and amphoteric ionic surfactant, comprise, for example: lauryl sodium sulfate, N-dodecyl sulaine, TweenTM80, cetyl trimethylammonium bromine, ring-n-methyl-β-D-maltoside and n-hexyl-β-D-glucopyranoside. Non-ionic detergent is particularly preferred, particularly preferably ring-n-methyl-β-D-maltoside and n-hexyl-β-D-glucopyranoside. The content of detergent can be about 5-100mg/ml, preferably about 100 mg/ml.
The typical metal radionuclide that is used for the diagnostic imaging agent comprises different chlorides, oxide or nitride form99mTc、
64Cu、
67Cu、
97Ru、
109Pd、
198Au、
199Au、
111In. The typical metal radionuclide that is used for the radiotherapy purposes comprises different chlorides, oxide or nitride form186Re、
188Re、
111In、
166Ho、
105Rh、
149Pm、
153Sm、
177Lu、
90Y、
203Pb、
212Pb、
212Bi, radioactinium series elements and other radioactivity lanthanide series. With the preparation of the present invention isotope that to prepare radiopharmaceutic preferred radio isotope be technetium and rhenium (for example be used for94Tc、
99mTc、
186Re、
188Re). Most preferably, the isotope of use is99mTc, as pertechnetate,99mTcO
4 - Can add the about 100mCi's of about 5mCi-99mTc, the most preferably about 40mCi of about 20mCi-.
Radiopharmaceuticals preparation of the present invention can be used for preparing the radiopharmaceutical of rebuilding with radio isotope under the arbitrary temp between the room temperature to 100 ℃. When at room temperature preparing, optimum reacting time is about 10 minutes-Yue 60 minutes, more preferably about 15 minutes-Yue 30 minutes, and most preferably about 15 minutes. If be heated to 100 ℃ of preparations, when kit heated about 5 minutes-Yue 30 minutes, most preferably about 5 minutes-Yue 15 minutes the time, obtain the complex compound (＞90% RCP) of the hope of optimum point of production.
Randomly can contain solubilisation aids in the preparation of the present invention, such as cyclodextrin (for example α, β or γ cyclodextrin or hydroxypropyl-gamma-cyclodextrin). The γ cyclodextrin is preferred, and hydroxypropyl-gamma-cyclodextrin is most preferred. The concentration of cyclodextrin can be the about 10mg/mL of about 0.1mg/mL-, preferably the about 5mg/mL of about 2.5mg/mL-.
As shown in Figure 1, radiopharmaceutical of the present invention contains two or three domains: radioactive metal chelating moiety or chelating core, joint or linking group (if present), and receptor binding site or targeted molecular. Chelating moiety and targeted molecular perhaps do not contain joint with joint, can be called as cheland. Compound 1, a kind of preferred part for the preparation of radiopharmaceuticals preparation of the present invention has lower array structure:
Compound 1
Synthesizing in embodiment 1 of the trifluoroacetate of compound 1 and acetate described. Embodiment 2 described with99mThe preparation of the compound 1 of Tc complexing. In embodiment 3, (be the NMe of part by modifying the chelating core2-Gly-Ser-Cys part) structure has detected the effect of this chelating core. Particularly, as the part of experiment, synthesized compound 2-4, to detect the chelating core to the impact of RCP:
Chemical compound 2
Chemical compound 3
Chemical compound 4
Embodiment 3 describes, table 3 result displayed proves, compares with the preparation that contains chemical compound 2-4, and the radiopharmaceuticals preparation that contains chemical compound 1 shows outstanding RCP (promptly greater than 90%).
Embodiment 4 has described an embodiment of the test kit that is used to prepare radiopharmaceuticals preparation of the present invention, and the purposes of the technetium complex of preparation chemical compound 1.Embodiment 5-12 has described use detergent rather than diluent ethanol, the synthetic and comparative test of radiopharmaceutical compound.
Targeted molecular
Accept any molecule of the combination of part (combining) specificity or reactive combination or complexation with a kind of receptor or other, can in radiopharmaceuticals preparation of the present invention, be used as targeted molecular with the specified target cell colony.This cellular responsibility molecule, it randomly is connected with metal radionuclide chelating moiety by linking group, can be with attempt to combine or localized cell colony in conjunction with any molecule of, complexation or reaction.This cellular responsibility molecule is used for the particular target cell colony of this molecular reaction of Xiang Keyu and carries radiopharmaceutical.Targeted molecular can be non-peptide molecule, as steroid, carbohydrate, agglutinin or non-peptide micromolecule.Targeted molecular also can be a kind of antibody, as monoclonal antibody or polyclonal antibody or its fragment.Preferably, targeted molecular is a kind of peptide, plan peptide or class peptide.Most preferably, targeted molecular is a kind of peptide.The peptide that can be used as targeted molecular comprises: bombesin, gastrin, gastrin releasing peptide, transferrins, epidermal growth factor (" EGF "), platelet derived growth factor, tumor growth factor (" TGF "), as TGF-α and TGF-β, vaccinia growth factor (" VGF "), insulin and insulin-like growth factor I and II, urotensin I I peptide and analog, NP-Y peptide, octreotide, depreotide, vapreotide, vasoactive intestinal peptide (VIP), cholecystokinin (CCK), insulin like growth factor (IGF), the peptide receptor targeted that raises in blood vessel takes place is as vegf receptor (KDR for example, NP-1 etc.), contain the RGD peptide, melanotropin (MSH) peptide, neurotensin, calcitonin, peptide from the anti-tumour antibody complementary determining region, glutathion, YIGSR (leukocyte-avid peptide, for example P483H, its heparin land and lysine that contains PF4 (PF-4) is rich in sequence), atrial natriuretic peptide (ANP), beta amyloid peptide, δ-opium sample antagonist (as ITIPP (psi)), annexin-V, endothelin, IL-1/IL-1ra, IL-2, IL-6, IL-8, leukotriene B4 (LTB4), Chemotactic Peptide (as N-formyl-methionyl-leucyl-phenylalanine-lysine (fMLFK)), GP IIb/IIIa receptor antagonist (as DMP444), epidermal growth factor, people's neutrophil cell elastase inhibitor (EPI-HNE-2, HNE2 and HNE4), plasmin inhibitor, antimicrobial peptide, apticide (P280), P274, the thrombospondin receptor (comprises analog, as TP-1300), bitistatin, pituitary adenylate cyclase I receptor (PAC1), and the analog of these peptides and conservative substitution.
In preferred embodiments, the targeted molecular that uses in radiopharmaceuticals preparation of the present invention is a kind of biologically active peptide.The most preferred embodiment of the present invention comprises and gastrin releasing peptide receptor (GRP-r) bonded peptide, particularly bombesin analog that the latter is a kind of agonist, and as U.S. Patent number 6,200,546 is disclosed.The example of these peptides is listed in table 1.Some other bombesin analog, fragment or plan peptide also can be used as targeted molecular.For example, NAc-BBN[7-14] be accredited as reservation nanomole binding affinity and caused bioactive minimal segment.Yet, in bombesin 7-14 amino acid whose land, have the concrete amino acid replacement of minority (D-Ala for example
11Displacement L-Gly
11Or D-Trp
8Displacement L-Trp
8), these displacements may not reduce binding affinity, perhaps this chemical compound are become antagonist by agonist.For example, exist methionine (Met) to produce excited characteristic usually, and the disappearance of this residue produce antagonistic properties [people .Life Science (1989) 45 (17) such as R.Camble, 1521-7] usually at site BBN-14 place.
In addition, when chelate, solubilizing group or joint are connected in N when end of 7-14 amino acid residue of bombesin, difference in functionality had toleration.When bombesin or bombesin analog in radiopharmaceuticals preparation of the present invention during as biologically active peptide, this radiopharmaceutical can be by the tissue of targeted expression GRP receptor, particularly cancerous cell.
The aminoacid sequence of some natural bombesin-like peptide of table 1.
| Title | Sequence |
| Bombesin (BBN) | PGlu-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu -Met-NH 2(SEQ?ID?NO：1) |
| Alytensin | PGlu-Gly-Arg-Leu-Gly-Thr-Gln-Trp-Ala-Val-Gly-His-Leu -Met-NH 2(SEQ?ID?NO：2) |
| H-GRP | Val-Pro-Leu-Pro-Ala-Gly-Gly-Gly-Thr-Val-Leu-Thr-Lys- Met-Tyr-Pro-Arg-Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu- Met-NH 2(SEQ?ID?NO：3) |
| Litorin | PGlu-Gln-Trp-Ala-Val-Gly-His-Phe-Met-NH 2(SEQ?ID NO：4) |
| Pipinin | PGlu-Val-Pro-Gln-Trp-Ala-Val-Gly-His-Phe-Met-NH 2(SEQ?ID?NO：5) |
| People's neuromedin B | Ala-Pro-Leu-Ser-Trp-Asp-Leu-Pro-Glu-Pro-Arg-Ser-Arg- Ala-Ser Lys-Ile-Arg-Val-His-Ser-Arg-Gly-Asn-Leu-Trp-Ala-Thr-G ly-His-Phe-Met-NH 2(SEQ?ID?NO：6) |
| Phyllolitorin | PGlu-Leu-Trp-Ala-Val-Gly-Ser-Phe-Met-NH 2(SEQ?ID NO：7) |
Connect base
Term " spacer ", " at interval base ", " joint " are identical in this implication with " being connected basic ", be meant a kind of chemical group, it is used for coupling targeted molecular and metal-chelator, and can influence the metal complex function of the target function or the metal-chelator of targeted molecular sharply.The proper spacing base comprises the combination of independent peptide (aminoacid that promptly links together), non-peptide group (for example hydrocarbon chain) or aminoacid sequence and non-peptide spacer.Pure peptide spacer is made up of a series of aminoacid (for example Diglycocol, triglycine, Gly-Gly-Glu, Gly-Ser-Gly etc.), and wherein the total atom number between the metal-chelator is less than or equals 12 atoms in the N of BBN bound fraction end residue and the polymeric chain.
Spacer also can comprise a hydrocarbon chain (promptly-R
1-(CH
2)
n-R
2-), n=0-10 wherein, n=3-9 preferably, R
1Be a kind of derivant (H for example of group
2N-, HS-,-COOH), it can be as the site of covalently bound part skeleton or preformed metal-chelator or metal complex skeleton; R
2Be the N end NH that is used for the covalent coupling targeted molecular
2The group of-Ji (R for example
2Be an activated COOH yl).The chemical method of several coupling parts (being chelating agen) or preferred metallo-chelate and biomolecule has been described in the document.Referring to, for example, Wilbur (1992) Bioconj.Chem., 3:433; Parker (1990) Chem.Soc.Rev., 19:271; Hermanson (1996) " biological coupling technology " (Bioconjugate Techniques), Academic Press, pp.3-136; People such as Fritzberg (1995) " radio-labeled that is used for the antibody of targeting diagnosis ", " orientation of photographic developer is carried " (Targeted Delivery of Imaging Agents) V.P.Torchilin writes, CRCPress, Boca Raton, FL, pp.84-101 (all be incorporated by reference in this text and examine).Can utilize one or more such methods not the part of complexation (chelating agen) or radiation metallo-chelate be connected with base at interval, perhaps will basicly at interval be connected with targeted molecular.These methods comprise the formation of anhydride, aldehyde, aryl isothiocyanic acid, Acibenzolar or N-hydroxy-succinamide.A kind of preferred linking group is-the Gly-5-aminovaleric acid-.The U.S. serial of submitting in the unsettled patent application U.S. serial 60/439,722 that on January 13rd, 2003 submitted to and on January 13rd, 2,003 10/341,577 discloses and has been applicable to some other joint of the present invention, and its complete content is incorporated herein by reference.
The preparation of radiopharmaceutical and other preparation composition
The present invention also provides stable radiopharmaceuticals preparation, and it contains additive suitable and commonly used, as buffer, filler etc.In the another one embodiment, the present invention also can comprise and utilizes radiopharmaceutic single dose of formulation preparation of the present invention and/or multiple dose test kit.All on-radiation reagent of said preparation can be formulated together in a bottle, and perhaps complexing ligand may reside in the bottle, and Ya Xi or other reduction source may reside in second bottle.In the another one embodiment, this test kit can comprise transfer (or trans chelating) part and Ya Xi or other Reducing agent in first bottle, contain complexing ligand in second bottle.In the another one embodiment, this kit preparation can comprise and well known to a person skilled in the art typical additives and filler.Method of rebuilding this test kit with radiosiotope as well known to those skilled in the art.
Test kit of the present invention contains one or more bottles, the sterile preparation that contains the complexing ligand that pre-determines content in the bottle, other composition randomly is as Reducing agent, transfer ligand, buffer, lyophilization aid or filler, stabilization aid, solubilisation aids, antibacterial and diluent.Contain one or more optional ingredients in the preparation and make the end user be easier to synthesis of radiopharmaceuticals usually, be easier to produce test kit, and prolong the storage life of test kit, or improve stability of radioactive drugs and storage life.Containing the improvement that optional ingredients reaches in the preparation must weigh mutually with the preparation complexity that increases and the test kit production cost of increase.The one or more bottles that contain all or part preparation can be the form of sterile solution or lyophilized solid independently.
In the preparation radiopharmaceutical and can be used for preparing buffer useful in the radiopharmaceutic diagnostic kit and include but not limited to phosphoric acid, citric acid, sulfosalicylic acid and acetate buffer.In American Pharmacopeia, can see more complete tabulation.
In radiopharmaceuticals preparation of the present invention, randomly can use lyophilization aid or filler.Lyophilizing and filler comprise known in this field: mannitol, lactose, sodium chloride, maltose, sucrose, PEG 8000, cyclodextrin, and as hydroxypropyl-gamma-cyclodextrin (HP-γ-CD), glucosan, Ficoll and polyvinylpyrrolidone (PVP).Wherein, sodium chloride, maltose, HP-γ-CD and glucosan are to be used for preferred filler of the present invention, and HP-γ-CD is most preferred.
Useful stabilization aid or stabilizing agent comprise but are not limited in radiopharmaceuticals preparation of the present invention: ascorbic acid, para-amino benzoic acid (PABA), sodium sulfite, sodium pyrosulfite, gentisic acid, the tert-butyl alcohol and inositol.Gentisic acid is most preferred stabilization aid.
In the preparation radiopharmaceutical and can be used for preparing solubilisation aids useful in the radiopharmaceutic diagnostic kit and include but not limited to: ethanol, glycerol, Polyethylene Glycol, propylene glycol, polyoxyethylene sorbitan monoleate, dehydrating sorbitol monooleate, polysorbate, poly-(oxygen ethylene) block copolymer (Pluronics) of poly-(oxygen ethylene) poly-(oxypropylene) and lecithin.Preferred solubilisation aids is an ethanol.
As mentioned above, in preparation of the present invention, randomly contain detergent, to help to improve the yield that from bottle, reclaims radioactive product.These detergents can comprise nonionic, cation, anion and amphoteric ionic surfactant, comprise, for example: sodium lauryl sulphate, N-dodecyl sulaine, Tween
TM80, cetyl trimethylammonium bromine, ring-n-methyl-β-D-maltoside and n-hexyl-β-D-glycopyranoside.The two kinds of compositions in back are particularly preferred.The content of detergent can be about 5-100mg/ml, preferably about 100mg/ml.
In the preparation radiopharmaceutical and can be used for preparing antibacterial useful in the radiopharmaceutic diagnostic kit and include but not limited to: benzylalcohol, Benasept, methaform and methyl butex, propylparaben or oxybenzene butyl formate.
A kind of composition in the diagnostic kit also can be exercised more than one function.Reducing agent also can be as stabilization aid, and buffer or stabilizing agent also can be as transfer ligands, lyophilization aid also can as shift, auxiliary or collaborative part, or the like.
In a preferred embodiment, test kit of the present invention comprises: a kind of targeting cheland of structure shown in the general formula I; A kind of tin salt is as stannous chloride, stannous fluoride or stannous tartrate; A kind of stabilization aid is as gentisic acid or the acceptable salt of its pharmacy; A kind of exchange part is as gluconic acid or the acceptable salt of its pharmacy; With a kind of solubilizing agent, as ethanol and/or cyclodextrin, as hydroxypropyl γ cyclodextrin.Most preferably, this test kit comprises one or two bottle.In an especially preferred embodiment, this test kit comprises two bottles, and first bottle contains 4 μ g chemical compounds 1 (triflate or acetate); 40 μ g SnCl
22H
2O; 1.3mg gluconic acid, sodium salt; The 20mg gentisic acid, sodium salt; 2.5mg hydroxypropyl-gamma-cyclodextrin randomly with acceptable acid of a kind of pharmacy or alkali, as HCl or NaOH, is about pH3-4 with the pH regulator of said preparation; Second bottle contains ethanol.
Use following abbreviation: TFA in an embodiment, trifluoroacetic acid; HOBt, I-hydroxybenzotriazole; DIC, N, N '-DIC; HATU, O-(7-azepine benzo triazol-1-yl)-1,1,3,3-tetramethylurea hexafluorophosphoric acid; DIEA, diisopropylethylamine; DMF, dimethyl formamide; DMSO, methyl sulfoxide; CH
2Cl
2, dichloromethane; EtOH, ethanol.RCP, radiochemical purity; HPLC, high pressure liquid chromatography.Unless otherwise noted, all material need not be further purified and can use all available from Aldrich.Fmoc-5-amino-valeric acid (5-ava) is available from Chem-Impex International.All Fmoc-aminoacid are all available from Novabiochem.
Embodiment 1
The solid-phase peptide of chemical compound 1 is synthetic
Scheme 1
Chemical compound 1 adopts the solid phase method of peptide synthesis (SPPS) to be prepared as TFA and acetate according to the following stated program.Unless otherwise noted, all material need not be further purified and can use all available from Aldrich.
Synthesizing of the tfa salt of chemical compound 1:
Shown in above-mentioned scheme 1, synthesizing of this chemical compound uses HOBt/DIC to activate on rink-amide Novagel resin, carries out in dimethyl formamide (DMF).Carry out Fmoc with 20% piperidines that is dissolved in DMF and go protection.Resin is swelling 1 hour in DMF before use.Except last N, beyond the coupling of N-dimethylglycine, all couplings all continue 2 hours (seeing below).Utilize finishing of ninhydrin test detection reaction.
A typical coupling circulation is as follows: to containing the swollen resin (0.6mmol/g of 1.13mmol, Novabiochem) add a kind of solution in the 50-mL SPPS reaction vessel, this solution contains the 4.52mmol Fmoc-aminoacid that is dissolved in DMF (EM Science), 4.52mmolHOBT (Novabiochem) and the 4.52mmol DIC that is dissolved in DMF.The cumulative volume of DMF is 20mL.Reactant mixture vibration 2 hours.Filter resin then, with DMF washing (3 * 30mL).Carry out ninhydrin test, confirm link coupled finishing.In resin, add the solution of 20% piperidines in DMF (20mL), vibrated 10 minutes.Filter resin, repeat this piperidines and handle.Last usefulness DMF washing resin in preparation process (3 * 30mL), carry out next coupling circulation.
In the end coupling circulation time, utilize HATU/DIEA to activate coupling N, N-dimethylglycine.Therefore, to N, adding is dissolved in the 4.52mmol HATU (Perseptive Biosystems) of DMF and the solution of 9.04mmolDIEA in the suspension of N-dimethylglycine (4.52mmol) in DMF.Clear solutions is added in the resin, vibrated 16 hours.After synthetic, resin is with DMF (3 * 30mL) and CH
2Cl
2(3 * 30mL) washings.Use N
2Blow by container and to carry out drying in 15 minutes.Add 30mL reagent B (TFA/ phenol/H
2O/ tri isopropyl silane/dimethyl sulfide 86mL/5g/5mL/2mL/2mL), vibration is 4 hours.Filter resin, make filtrate be evaporated to paste.Thick peptide precipitates in ether, uses the ether washed twice.Dry back obtains the thick material of 1.2g.Utilize ShimadzuHPLC system and this peptide of YMC C-18 preparative column purification.Thick substance dissolves is in 15%CH
3CN/H
2Among the O (0.1%TFA), upper prop.Gradient is included in 4 minutes and brings up to 19%CH by 15%
3CN/H
2O (0.1%TFA) brought up to 49% by 19% subsequently in 60 minutes.Merge and these fraction of lyophilizing.Obtain the 840mg pure material altogether.
Synthesizing of the acetate of chemical compound 1:
The tfa salt (110mg is in 20mL 0.5M HOAc) of chemical compound 1 is added on the 30-mLAG 1X2 ion exchange resin column (acetate type, Bio-Rad Laboratories).The resin water washs in advance, up to obtaining constant electrical conductivity.With the flow velocity eluting of 0.5M HOAc with 12mL/min.The fraction that merging and lyophilizing are wished.Note avoiding making material to be exposed to air for a long time.Obtain the acetate of 90mg chemical compound 1.
Embodiment 2
Be used for the preparation with
99mThe preparation of the chemical compound 1 of Tc complexation
In 0.05N HCl or 0.1%TFA, be prepared as the concentration of 0.08mg/mL as the solution of the tfa salt of synthetic chemical compound 1 as described in the embodiment 1.The preparation method of the gentisic acid solution of pH3 is: with gentisic acid, sodium salt (Sigma) is dissolved as the concentration of 100mg/mL, and is 2.9-3.0 with HCl (1N) with pH regulator.Stannous chloride solution (20mg/mL) passes through SnCl
22H
2O is dissolved in N
2Preparation among the HCl (1N) that purifies.The inferior solution of tin of gluconic acid prepares by 20 μ L stannous chloride solutions are added in the 1mL gluconic acid sodium salt solution.Hydroxypropyl-γ cyclodextrin solution (50mg/mL) passes through HP-γ-CD preparation soluble in water.All solvents that are used for preparing these solution all purify with nitrogen.
In order to prepare chemical compound 1
99mThe Tc complex adds 300 μ L ethanol, 50 μ L ligand solutions (4 μ g chemical compound 1), 200 μ L gentisic acid solution (20mg), inferior solution of tin (the 40 μ g SnCl of 50 μ L hydroxypropyls-gamma-cyclodextrin solution (2.5mg) 100 μ L gluconic acids
2) and
99mTcO
4 -(～40mCi).Add water, making final volume is 1.0mL, and reaction system heated 15-20 minute down at 100 ℃.
Use the Vydac C18 protein and the peptide analysis post of 300A aperture, 4.6 * 250mm column length, measure by HPLC
99mThe peptide purity of Tc labelling.Use following gradient (flow velocity is 1mL/min): isocratic elution 78%H
2O (0.1%TFA)/22%CH
3CN (0.1%TFA) 20 minutes, gradient dropped to 40%CH from 78% in 5 minutes
3CN (0.1%TFA) is at 40%CH
3CN (0.1%TFA) kept 10 minutes, was elevated to 78%CH from 40% in 5 minutes
3CN (0.1%TFA).
Use is with 60%CH
3CN/30%H
2O/10%NH
4(10 * 2cm) plates are measured the percentage ratio of radiocolloid in the radiolabeled product to the C18 of OH eluting.2 μ L equal portions reactant mixtures are at 1.5cm place point sample, and plank launches to reach 9.5cm.These planks are counted with Bioscan RadiochromatoscanAR2000 type.Represent the % radiocolloid in the activity that 0-2cm measures.The preparation of this embodiment preparation is being used 40mCi
99mTcO
4 -Rebuild after 18 minutes, radiochemical purity (RCP) value is to be～91% after～93%, 6 hours.
Embodiment 3
The chelating core is to the influence of RCP
Carry out following experiment, check of the influence of chelating core RCP.The tfa salt ((NMe of chemical compound 1
2-Gly-Ser-Cys)-Gly-(5-aminovaleric acid)-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH
2) as described in embodiment 1, synthesize.Suitable improvement according to embodiment 1 described synthetic method prepares the chemical compound shown in the table 2 by the solid phase method of peptide synthesis.
The structure of other chemical compound that table 2. embodiment 3 uses
| Compound number | Structure |
| 2 | ?NMe 2Amino valeryl-the Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH of-Gly-Gly-Cys-Gly-5- 2 |
| 3 | ?NH 2Amino valeryl-the Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH of-Gly-Ser-Cys-Gly-5- 2 |
| 4 | ?NH 2Amino valeryl-the Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH of-Gly-Gly-Cys-Gly-5- 2 |
The solution of chemical compound 1-4 is prepared as the concentration of 0.08mg/mL in 0.05N HCl.The gentisic acid solution of pH3 is prepared as follows: with the gentisic acid sodium salt (223mg, Sigma) water-soluble, be 3.0 with HCl (1N) with pH regulator.The final volume of solution is 2.79mL.Stannous chloride solution passes through SnCl
22H
2(1.547mg, 0.007mmol Aldrich) are dissolved in 500 μ L N to O
2Prepare among the 0.05N HCl that purifies.Adding 51mg (0.23mmol) gentisic acid sodium salt (Sigma) in this solution, is 2978 μ L with volume-adjustment.All solvents that are used for preparing these solution all purify with nitrogen.
In order to prepare
99mThe Tc complex adds 50 μ L ligand solutions (4 μ g chemical compound 1-4), 300 μ LEtOH, 250 μ L gentisic acid solution (20mg), 50 μ L 1SnCl
2: 34 gluconic acids (40 μ g SnCl
2) and
99mTcO
4 -(～40mCi, Syncor).Add water, making final volume is 1.0mL, and reaction system was at room temperature placed 15 minutes.Then as the RCP of analytical solution as described in the embodiment 2.The result is as shown in table 3.
The HPLC of table 3. chemical compound 1-4 analyzes, average RCP value
| Chemical compound | Percentage RCP in the time of 15 minutes | Percentage RCP in the time of 6 hours | The percentage radiocolloid |
| ????1 | ????91.2 | ????88.1 | ????1.2 |
| ????2 | ????80.8 | ????78.7 | ????0.95 |
| ????3 | ????86.7 | ????82.4 | ????0.31 |
| ????4 | ????83.3 | ????83.3 | ????2 |
Each experiment is all carried out repeatedly, its meansigma methods of table 3 report.
Embodiment 4
Be used to prepare TcOMe
2The amino valeryl of N-Gly-Ser-Cys-Gly-5-
-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH
2Test kit
This embodiment describes a kind of radiopharmaceutic bi-component test kit of the present invention that is used to prepare.As shown in table 4, this test kit can comprise two bottles, but this test kit needn't provide the content of the 2nd bottle.
Table 4. test kit that is used to prepare radiopharmaceuticals preparation of the present invention
| Bottle 1 | Bottle 2 |
| 4 μ g chemical compounds 1 (triflate or acetate), 40 μ g SnCl 2·2H 2O 1.3mg gluconic acid, sodium salt 20mg gentisic acid, sodium salt 2.5mg hydroxypropyl-gamma-cyclodextrin (choosing wantonly) pH3-4 | 300μL?EtOH |
300 μ L EtOH of bottle 1 usefulness bottle 2 rebuild, and add 40mCi
99mTcO
4 -, adding normal saline subsequently, to make final volume be 1.0mL.This bottle was at room temperature placed 15 minutes then, perhaps heated 5-20 minute down at 100 ℃.As shown in table 4, contain hydroxypropyl-gamma-cyclodextrin and choose wantonly.
The application of detergent in lyophilized formulations
Described in the past for synthetic
99mTc-the chemical compound 1 and preparation of development contains 30% (300 μ l) EtOH is used for improving reclaiming from bottle
99mThe yield of Tc complex.If wish it is cryodesiccated test kit, EtOH needs the preparation of two bottles as a kind of liquid, because it can not be with other preparation composition lyophilization.Use a kind of solid chemical compound to replace EtOH can make the quantity of bottle be kept to 1, thereby may reduce production costs greatly by 2.
Two kinds of non-ionic detergents have been detected: cyclohexyl-n-methyl-β-D-maltoside and n-hexyl-β-D-glycopyranoside for this reason.
Cyclohexyl-n-methyl-β-D-maltoside n-hexyl-β-D-glycopyranoside
Select these detergents to be because they should not dissolve biomembrane (they are not ionic detergents), they have extremely strong water solublity, contain a sugar moieties with potential exchange part characteristic.
Embodiment 5
99mNot synthetic (not the adding ethanol or surfactant) of Tc chemical compound 1
By with 2.303mg (0.001mmol) SnCl
22H
2O is dissolved in 500 μ L N
2The inferior solution of tin of preparation gluconic acid among the 0.05N HCl that purifies.Add 76mg (0.347mmol) gluconic acid sodium salt in this solution, water is 2.878mL with volume-adjustment.
Chemical compound 1 (275 μ g, chemical compound 1 acetate) is dissolved among the 2.750mL 0.05N HCl.(158.6mg) is water-soluble for gentisic acid, is 3.0 with 1N HCl with pH regulator; Final volume is 2.08mL.
In 50 μ L chemical compounds, 1 solution (4 μ g), add
99mTcO
4 -(190 μ L, 41.5mCi), 0.458mL H
2O, inferior solution of tin (the 40 μ g SnCl of 50 μ L gluconic acids
2) and 262 μ L gentisic acid solution (20mg).Reaction system heated 5 minutes down at 100 °, carried out HPLC with following system afterwards and analyzed: and Vydac C-18 protein and peptide post (4.6 * 250mm), use 78%H
2O (0.1%TFA)/22%CH
3CN (0.1%TFA) eluting 20 ' is promoted to 40%H from 78% in 5 '
2O (0.1%TFA) is at 40%H
2O (0.1%TFA) keeps 10 ', is promoted to 78%H from 40% then in 5 '
2O (0.1%TFA).Flow velocity: 1mL/min.The RCP that obtains is 87.1% when being initially 87.4%, 6 hour.The yield that reclaims from bottle is 67%.
This embodiment demonstration, under the situation of not adding ethanol or surfactant,
99mTc chemical compound 1 is lower from the yield that bottle reclaims.
Embodiment 6
Synthetic with 300 μ l EtOH
99mTc chemical compound 1 (surfactant-free)
The inferior stannum of gluconic acid, chemical compound 1 and gentisic acid solution are as preparation as described in the embodiment 5.In 50 μ L chemical compounds, 1 solution (4 μ g), add
99mTcO
4 -(170 μ L, 38.5mCi), 0.178mL H
2O, inferior solution of tin (the 40 μ g SnCl of 50 μ L gluconic acids
2), 262 μ L gentisic acid solution (20mg) and 300 μ LEtOH.This reaction system is as heating and analysis as described in the embodiment 5.The RCP that obtains is 91.1-93.1%, is 87.0-90.3% in the time of 6 hours.Observe 0.5 and 0.7 radiocolloid value (n=2).The yield that reclaims from bottle is 98.44% (n=1).
This embodiment shows, with EtOH replace in the preparation-a little water can improve
99mThe yield that Tc chemical compound 1 reclaims from bottle.
Embodiment 7
Synthetic with 10mg cyclohexyl-n-methyl-β-D-maltoside
99mTc chemical compound 1
By with 1.597mg (0.007mmol) SnCl
22H
2O is dissolved in 500 μ L N
2The inferior solution of tin of preparation gluconic acid among the 0.05N HCl that purifies.Add 51mg (0.233mmol) gluconic acid sodium salt in this solution, water is 1.996mL with volume-adjustment.Chemical compound 1 (211 μ g, chemical compound 1 acetate) is dissolved among the 2.637mL 0.05N HCl.(238.8mg) is water-soluble for gentisic acid, is 3.0 with 1N HCl with pH regulator; Final volume is 3.085mL.Cyclohexyl-n-methyl-β-D-maltoside (55mg) is dissolved in 550 μ L H
2Among the O.
In 50 μ L chemical compounds, 1 solution (4 μ g), add
99mTcO
4 -(270 μ L, 38mCi), 0.272mL H
2O, inferior solution of tin (the 40 μ g SnCl of 50 μ L gluconic acids
2), 258 μ L gentisic acid solution (20mg) and 100 μ L (10mg) maltoside solution.Reaction system is as heating and analysis as described in the embodiment 5.The RCP that obtains is 88.2%, and the percentage ratio of radiocolloid is 1.3%.
This embodiment shows, compares with not containing maltoside (embodiment 5), and adding maltoside does not influence
99mThe output of Tc chemical compound 1.
Embodiment 8
Synthetic with 15mg cyclohexyl-n-methyl-β-D-maltoside
99mTc chemical compound 1
The inferior stannum of gluconic acid, chemical compound 1 and gentisic acid solution are as preparation as described in the embodiment 5.Cyclohexyl-n-methyl-β-D-maltoside (36.2mg) is dissolved in 518 μ L H
2Among the O.In 50 μ L chemical compounds, 1 solution (4 μ g), add
99mTcO
4 -(210 μ L, 38.4mCi), 0.338mL H
2O, inferior solution of tin (the 40 μ g SnCl of 50 μ L gluconic acids
2), 262 μ L gentisic acid solution (20mg) and 100 μ L (15mg) maltoside solution.Reaction system is as heating and analysis as described in the embodiment 5.The RCP that obtains is 88.0%, and the yield that reclaims from bottle is 90.3%.
This embodiment shows, with respect to the condition that embodiment 5 uses, adds cyclohexyl-n-methyl-β-D-maltoside and can improve from bottle and reclaim in bottle
99mThe yield of Tc chemical compound 1, and can influence RCP sharply.
Embodiment 9
Synthetic with 50mg cyclohexyl-n-methyl-β-D-maltoside
99mTc chemical compound 1
The inferior stannum of gluconic acid, chemical compound 1 and gentisic acid solution are as preparation as described in the embodiment 7.Cyclohexyl-n-methyl-β-D-maltoside (85mg) is dissolved in 510 μ L H
2Among the O.In 50 μ L chemical compounds, 1 solution (4 μ g), add
99mTcO
4 -(230 μ L, 39.6mCi), 0.168mL H
2O, inferior solution of tin (the 40 μ g SnCl of 50 μ L gluconic acids
2), 262 μ L gentisic acid solution (20mg) and 300 μ L (50mg) maltoside solution.Reaction system is as heating and analysis as described in the embodiment 5.The RCP that obtains is 88.5% and 90.5%.The yield that reclaims from bottle is 95.6% (n=1).
This embodiment shows, with respect to the condition that embodiment 5 uses, adds cyclohexyl-n-methyl-β-D-maltoside and can improve from bottle and reclaim in bottle
99mThe yield of Tc chemical compound 1, and can influence RCP sharply, with respect to using the 15mg surfactant, use the 50mg surfactant can improve yield.
Embodiment 10
Synthetic with 100mg cyclohexyl-n-methyl-β-D-maltoside
99mTc chemical compound 1
The inferior stannum of gluconic acid, chemical compound 1 and gentisic acid solution are as preparation as described in the embodiment 7.Cyclohexyl-n-methyl-β-D-maltoside (127.9mg) is dissolved in 518 μ L H
2Among the O.In 50 μ L chemical compounds, 1 solution (4 μ g), add
99mTcO
4 -(220 μ L, 41.6mCi), 0.022mL H
2O, inferior solution of tin (the 40g μ SnCl of 50 μ L gluconic acids
2), 258 μ L gentisic acid solution (20mg) and 400 μ L (10mg) maltoside solution.Reaction system is as heating and analysis as described in the embodiment 5.The RCP that obtains is 90%.The percentage ratio of radiocolloid is 0.5%.
Embodiment 11
Synthetic with 10mg n-hexyl-β-D-glycopyranoside
99mTc chemical compound 1
By with 2.383mg (0.001mmol) SnCl
22H
2O is dissolved in 500 μ L N
2The inferior solution of tin of preparation gluconic acid among the 0.05N HCl that purifies.Add 78mg (0.36mmol) gluconic acid sodium salt in this solution, water is 2.978mL with volume-adjustment.Chemical compound 1 (265 μ g) (acetate) is dissolved among the 2.650mL 0.05N HCl.(204.1mg) is water-soluble for gentisic acid, is 3.0 with 1N HCl with pH regulator; Final volume is 2.551mL.N-hexyl-β-D-glycopyranoside (180.6mg) is dissolved in 672 μ L H
2Among the O.
In 50 μ L chemical compounds, 1 solution (4 μ g), add
99mTcO
4 -(210 μ L, 38mCi), 0.41mL H
2O, inferior solution of tin (the 40 μ g SnCl of 50 μ L gluconic acids
2), 250 μ L gentisic acid solution (20mg) and 40 μ L (10mg) maltoside solution.Reaction system is as heating and analysis as described in the embodiment 5.The RCP that obtains is 86.4%, and the percentage ratio of radiocolloid is 1.1%.The yield that reclaims from bottle is 96.3%.
This embodiment shows, compares with the condition that embodiment 5 uses, and adds n-hexyl-β-D-glycopyranoside and can improve from bottle and reclaim in bottle
99mThe yield of Tc chemical compound 1 can influence RCP sharply.
Embodiment 12
Synthetic with 50mg n-hexyl-β-D-glycopyranoside
99mTc chemical compound 2
The inferior stannum of gluconic acid, chemical compound 1 and gentisic acid solution are as preparation as described in the embodiment 11.N-hexyl-β-D-glycopyranoside (180.6mg) is dissolved in 672 μ L H
2Among the O.
In 50 μ L chemical compounds, 1 solution (4 μ g), add
99mTcO
4 -(160 μ L, 41mCi), 0.3mL H
2O, inferior solution of tin (the 40 μ g SnCl of 50 μ L gluconic acids
2), 250 μ L gentisic acid solution (20mg) and 200 μ L (50mg) maltoside solution.Reaction system is as heating and analysis as described in the embodiment 5.The RCP that obtains is 89.1% when being initially 92.7%, 6 hour.The percentage ratio of radiocolloid is 1.2%, and the yield that reclaims from bottle is 98.8%.Below shown a typical chromatogram.
Sum up
As shown in the table, the yield that uses these detergents to obtain is closely similar with the yield that uses EtOH.And the RCP that obtains with n-hexyl-β-D-glycopyranoside is suitable with the RCP that uses EtOH to obtain.
| Detergent | Initial RCP (%) | 6 hours RCP (%) | Colloid (%) | Yield (%) |
| No EtOH | 87.4 | ?87.1 | ?67.0 | |
| ?EtOH | 93.1 | ?88.2 | ?98.4 | |
| ?EtOH | 92.5 | ?90.3 | ?0.7 | |
| ?EtOH | 91.1 | ?87.0 | ?0.5 | ?98.6 |
| The 10mg maltoside | 88.2 | ?1.3 | ||
| The 15mg maltoside | 88.0 | ?90.3 | ||
| The 50mg maltoside | 88.5 | ?95.6 | ||
| The 50mg maltoside | 90.5 | ?85.2 | ?1 | |
| The 100mg maltoside | 90.0 | ?0.5 | ||
| The 10mg glycopyranoside | 86.4 | ?1.1 | ?96.3 | |
| The 50mg glycopyranoside | 90.8 | ?0.4 | ||
| The 50mg glycopyranoside | 92.7 | ?89.1 | ?1.2 | ?98.8 |
Other embodiment
According to above description, obviously can the present invention described herein be changed and modify, to adapt to different purposes and condition.
With reference to quoting
The open text of all that mention in this description, patent and patent application all are incorporated herein by reference, and independently openly text, patent and patent application be separately, quote as a reference particularly to be equal to each.
Sequence table
<110>Bracco?Imgaing?S.p.A.
＜120〉radiopharmaceuticals preparation
<130>57637-1081
＜140〉to be allocated
<141>2003-05-05
<160>7
<170>PatentIn?version?3.2
<210>1
<211>14
<212>PRT
＜213〉artificial
<220>
＜223〉artificial sequence description: synthetic peptide
<220>
<221>MOD_RES
<222>(1)..(1)
＜223〉pyroglutamic acid
<220>
<221>MOD_RES
<222>(14)..(14)
＜223〉amination methionine
<400>1
Glu?Gln?Arg?Leu?Gly?Asn?Gln?Trp?Ala?Val?Gly?His?Leu?Met
1???????????????5???????????????????10
<210>2
<211>14
<212>PRT
＜213〉artificial
<220>
＜223〉artificial sequence description: synthetic peptide
<220>
<221>MOD_RES
<222>(1)..(1)
＜223〉pyroglutamic acid
<220>
<221>MOD_RES
<222>(14)..(14)
＜223〉amination methionine
<400>2
Glu?Gly?Arg?Leu?Gly?Thr?Gln?Trp?Ala?Val?Gly?His?Leu?Met
1???????????????5???????????????????10
<210>3
<211>27
<212>PRT
＜213〉artificial
<220>
＜223〉artificial sequence description: synthetic peptide
<220>
<221>MOD_RES
<222>(27)..(27)
＜223〉amination methionine
<400>3
Val?Pro?Leu?Pro?Ala?Gly?Gly?Gly?Thr?Val?Leu?Thr?Lys?Met?Tyr?Pro
1???????????????5???????????????????10??????????????????15
Arg?Gly?Asn?His?Trp?Ala?Val?Gly?His?Leu?Met
20??????????????????25
<210>4
<211>9
<212>PRT
＜213〉artificial
<220>
＜223〉artificial sequence description: synthetic peptide
<220>
<221>MOD_RES
<222>(1)..(1)
＜223〉pyroglutamic acid
<220>
<221>MOD_RES
<222>(9)..(9)
＜223〉amination methionine
<400>4
Glu?Gln?Trp?Ala?Val?Gly?His?Phe?Met
1???????????????5
<210>5
<211>11
<212>PRT
＜213〉artificial
<220>
＜223〉artificial sequence description: synthetic peptide
<220>
<221>MOD_RES
<222>(1)..(1)
＜223〉pyroglutamic acid
<220>
<221>MOD_RES
<222>(11)..(11)
＜223〉amination methionine
<400>5
Glu?Val?Pro?Gln?Trp?Ala?Val?Gly?His?Phe?Met
1???????????????5???????????????????10
<210>6
<211>32
<212>PRT
＜213〉artificial
<220>
＜223〉artificial sequence description: synthetic peptide
<220>
<221>MOD_RES
<222>(32)..(32)
＜223〉amination methionine
<400>6
Ala?Pro?Leu?Ser?Trp?Asp?Leu?Pro?Glu?Pro?Arg?Ser?Arg?Ala?Ser?Lys
1???????????????5???????????????????10??????????????????15
Ile?Arg?Val?His?Ser?Arg?Gly?Asn?Leu?Trp?Ala?Thr?Gly?His?Phe?Met
20??????????????????25??????????????????30
<210>7
<211>9
<212>PRT
＜213〉artificial
<220>
＜223〉artificial sequence description: synthetic peptide
<220>
<221>MOD_RES
<222>(1)..(1)
＜223〉pyroglutamic acid
<220>
<221>MOD_RES
<222>(9)..(9)
＜223〉amination methionine
<400>7
Glu?Leu?Trp?Ala?Val?Gly?Ser?Phe?Met
1???????????????5
Claims (37)
1. radiopharmaceutical composition, it contains:
The chemical compound of general formula 1
General formula 1;
Reducing agent;
The exchange part;
Stabilizing agent;
Diluent; With
Radionuclide,
R wherein
1Be H, or linear or ramose, saturated or undersaturated C1-4 alkyl chain, it is randomly interrupted by the hetero atom that one or two is selected from N, O and S; And randomly replaced by at least one group that is selected from halogen, hydroxyl, amino, carboxyl, C1-4 alkyl, aryl and C (O) Z;
R
2Be R
1A substituent group of definition; Perhaps
R
1And R
2Can constitute the saturated or unsaturated heterocycle of a 5-8 unit together, it is randomly replaced by the group that at least one is selected from halogen, hydroxyl, amino, carboxyl, C1-4 alkyl, aryl and C (O) Z;
R
3Be-H ,-CH
2OH, C
2H
4OH or-tert-butyl group;
L chooses wantonly, and is a connection base;
Z is a targeted molecular.
2. one kind is used to prepare radiopharmaceutic compositions, and it contains:
The chemical compound of general formula 1
General formula 1;
Reducing agent;
The exchange part; With
Stabilizing agent;
R wherein
1Be H, or linear or ramose, saturated or undersaturated C1-4 alkyl chain, it is randomly interrupted by the hetero atom that one or two is selected from N, O and S; And randomly replaced by at least one group that is selected from halogen, hydroxyl, amino, carboxyl, C1-4 alkyl, aryl and C (O) Z;
R
2Be R
1A substituent group of definition; Perhaps
R
1And R
2Can constitute the saturated or unsaturated heterocycle of a 5-8 unit together, it is randomly replaced by the group that at least one is selected from halogen, hydroxyl, amino, carboxyl, C1-4 alkyl, aryl and C (O) Z;
R
3Be-H ,-CH
2OH, C
2H
4OH or-tert-butyl group;
L chooses wantonly, and is a connection base;
Z is a targeted molecular.
3. claim 1 or 2 compositions, wherein R
1And R
2It is methyl.
4. claim 1 or 2 compositions, wherein R
3Be-CH
2OH or C
2H
4OH.
5. claim 1 or 2 compositions, wherein R
1And R
2Be methyl, R
3Be-CH
2OH.
6. radiopharmaceutical composition, it contains the chemical compound of general formula 1a
Reducing agent;
The exchange part;
Stabilizing agent;
Diluent; With
Radionuclide,
Wherein L chooses wantonly, and is to connect base;
Z is a targeted molecular.
7. one kind is used to prepare radiopharmaceutic compositions, and it contains the chemical compound of general formula 1a
Reducing agent;
The exchange part; With
Stabilizing agent;
Wherein L chooses wantonly, and is to connect base; Z is a targeted molecular.
8. claim 1,2,6 or 7 compositions, wherein Z is the bombesin analog.
9. the compositions of claim 8, wherein Z is selected from SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; SEQ ID NO:6; With SEQ IDNO:7.
10. radiopharmaceutical composition, it contains:
The chemical compound of general formula 2
General formula 2;
Reducing agent;
The exchange part;
Stabilizing agent;
Diluent; With
Radionuclide.
11. one kind is used to prepare radiopharmaceutic compositions, it contains:
The chemical compound of general formula 2
General formula 2;
Reducing agent;
The exchange part; With
Stabilizing agent.
12. each compositions among the claim 1-11, wherein Reducing agent is selected from stannous salt, sodium borohydride, cupric salt, carbonamidine and sulfinic acid.
13. the compositions of claim 12, wherein Reducing agent is a stannous chloride.
14. each compositions among the claim 1-13 wherein exchanges part and is selected from gluconate, gentisic acid and gluceptate.
15. the compositions of claim 14, wherein exchanging part is gluconate.
16. each compositions among the claim 1-15, wherein stabilizing agent is selected from gentisic acid, maltose and ascorbic acid.
17. the compositions of claim 16, wherein stabilizing agent is a gentisic acid.
18. each compositions among the claim 1-17, it further contains solubilizing agent.
19. the compositions of claim 18, wherein solubilizing agent is a cyclodextrin.
20. the compositions of claim 19, wherein solubilizing agent is hydroxypropyl-gamma-cyclodextrin.
21. each compositions among claim 1,3-6,8-10, the 12-20, wherein diluent is selected from ethanol, water and saline.
22. the compositions of claim 21, wherein diluent is an ethanol.
23. a radiopharmaceutical composition, it contains:
The chemical compound of general formula 2
General formula 2;
Stannous chloride;
Gluconic acid;
Gentisic acid;
Ethanol; With
Radionuclide.
24. one kind is used to prepare radiopharmaceutic compositions, it contains:
The chemical compound of general formula 2
General formula 2;
Stannous chloride;
Gluconic acid; With
Gentisic acid.
25. the compositions of claim 23 or 24, it further contains hydroxypropyl-gamma-cyclodextrin.
26. each radiopharmaceutical composition among claim 1,3-6,8-10, the 12-22, the amount of the chemical compound of its formula of 1 is less than every mL diluent 10 μ g.
27. each radiopharmaceutical composition among claim 1,3-6,8-10, the 12-22, the amount of the chemical compound of its formula of 1 is less than every mL diluent 5 μ g.
28. each radiopharmaceutical composition among claim 1,3-6,8-10, the 12-22, wherein this radiopharmaceutical is not purified can prepare and the patient be used.
29. each radiopharmaceutical composition among claim 1,3-6,8-10, the 12-22, wherein at the RCP of about 15 minutes said compositions more than or equal to about 90%.
30. each compositions among claim 2-5,7-9, the 11-20 wherein contains the chemical compound of a certain amount of general formula 1, makes the every mL diluent of gained radiopharmaceutical contain less than 10 μ g.
31. each compositions among claim 2-5,7-9 or the 11-20 wherein contains the chemical compound of a certain amount of general formula 1, makes the every mL diluent of gained radiopharmaceutical contain less than 5 μ g.
32. each compositions among claim 2-5,7-9 or the 11-20, wherein the radiopharmaceutical of gained is not purified can prepare and the patient be used.
33. each compositions among claim 2-5,7-9 or the 11-20, wherein the radiopharmaceutic RCP of gained at about 15 minutes more than or equal to about 90%.
34. each compositions among the claim 1-32, it further contains detergent.
35. each compositions among claim 2-5,7-9,11-20 or the 29-33, it further contains detergent, and wherein said composition is a lyophilized form.
36. each compositions among claim 2-5,7-9,11-20 or the 29-33, it further contains diluent, randomly is contained in the container separately.
37. the compositions of claim 34, wherein detergent is cyclohexyl-n-methyl-β-D-maltoside or n-hexyl-β-D-glycopyranoside.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37745402P | 2002-05-03 | 2002-05-03 | |
| US60/377,454 | 2002-05-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1658907A true CN1658907A (en) | 2005-08-24 |
| CN100471523C CN100471523C (en) | 2009-03-25 |
Family
ID=29401500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB03812954XA Expired - Fee Related CN100471523C (en) | 2002-05-03 | 2003-05-05 | Radiopharmaceutical formulations |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7556795B2 (en) |
| EP (1) | EP1503804A4 (en) |
| JP (1) | JP4885448B2 (en) |
| CN (1) | CN100471523C (en) |
| AU (1) | AU2003239351B2 (en) |
| CA (1) | CA2485339C (en) |
| WO (1) | WO2003092743A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103435684A (en) * | 2013-09-23 | 2013-12-11 | 武汉工程大学 | 18F-fluorine labeling pentapeptide complex and synthetic method thereof |
| CN103467504A (en) * | 2013-09-23 | 2013-12-25 | 武汉工程大学 | 18F-fluorine labeled porphyrin-isoindoline free radical complex and synthesis method thereof |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7850947B2 (en) | 2003-01-13 | 2010-12-14 | Bracco Imaging S.P.A. | Gastrin releasing peptide compounds |
| US8420050B2 (en) | 2003-01-13 | 2013-04-16 | Bracco Imaging S.P.A. | Gastrin releasing peptide compounds |
| US7922998B2 (en) * | 2003-01-13 | 2011-04-12 | Bracco Imaging S.P.A. | Gastrin releasing peptide compounds |
| US7226577B2 (en) | 2003-01-13 | 2007-06-05 | Bracco Imaging, S. P. A. | Gastrin releasing peptide compounds |
| US7611692B2 (en) | 2003-01-13 | 2009-11-03 | Bracco Imaging S.P.A. | Gastrin releasing peptide compounds |
| CA2526556C (en) * | 2003-07-24 | 2012-09-25 | Bracco Imaging S.P.A. | Stable radiopharmaceutical compositions and methods for their preparation |
| US20090062509A1 (en) * | 2006-03-16 | 2009-03-05 | Aldo Cagnolini | Chelation of metals to thiol groups using in situ reduction of disulfide-containing compounds by phosphines |
| WO2008009444A1 (en) * | 2006-07-19 | 2008-01-24 | Van Dulmen, Adrianus, A. | Use of ethanol for stabilizing a single-vial liquid formulation of a radiolabeled peptide |
| WO2008079834A2 (en) * | 2006-12-21 | 2008-07-03 | Lantheus Medical Imaging, Inc. | Preparation of paramagnetic nanoparticles conjugated to leukotriene b4 (ltb4) receptor antagonists, and their use as mri contrast agents for the detection of infection and inflammation |
| US8436140B2 (en) * | 2008-06-02 | 2013-05-07 | Washington University | Natriuretic peptide-mediated imaging of atherosclerotic plaque |
| GB201402132D0 (en) * | 2014-02-07 | 2014-03-26 | South African Nuclear Energy | A method of producing ethylenedicysteine deoxyglucosamine (ECDG) or a salt thereof and its application in a kit |
| WO2019195890A1 (en) * | 2018-04-11 | 2019-10-17 | Clarity Pharmaceuticals Pty Ltd | Formulations and kits for radiotherapy and diagnostic imaging |
| GB201915206D0 (en) * | 2019-10-21 | 2019-12-04 | Ge Healthcare Ltd | Use of cyclodextrins as a radiostabilizer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4364920A (en) * | 1975-04-30 | 1982-12-21 | Medi-Physics, Inc. | Stable diagnostic reagents |
| US4233284A (en) * | 1978-03-31 | 1980-11-11 | The Procter & Gamble Company | Stabilized radiographic scanning agents |
| DE78642T1 (en) * | 1981-10-30 | 1983-10-27 | Amersham International Plc, Amersham, Buckinghamshire | RADIOPHARMACEUTICAL PREPARATION BASED ON TECHNETIUM-99M AND REAGENT FOR THE PRODUCTION THEREOF. |
| US5753206A (en) | 1995-06-07 | 1998-05-19 | Immunomedics, Inc. | Radiometal-binding analogues of luteinizing hormone releasing hormone |
| US20020119438A1 (en) * | 1995-12-29 | 2002-08-29 | Fuminori Kato | Method for determining viable cell count |
| EP1005479A4 (en) * | 1997-04-10 | 2002-12-18 | Life Technologies Inc | Rna isolation reagent and methods |
| JP2002506424A (en) | 1997-04-22 | 2002-02-26 | キュレイター オブ ザ ユニバーシィティ オブ ミズーリ | Gastrin receptor-affinity peptide conjugate |
| CA2346154A1 (en) * | 2001-05-02 | 2002-11-02 | University Of Missouri | Gastrin receptor-avid peptide conjugates |
| US6056941A (en) * | 1999-07-28 | 2000-05-02 | Bracco Research Usa | Kit for the preparation of technetium TC 99m teboroxime myocardial perfusion agent |
| US6685914B1 (en) * | 1999-09-13 | 2004-02-03 | Bristol-Myers Squibb Pharma Company | Macrocyclic chelants for metallopharmaceuticals |
-
2003
- 2003-05-05 US US10/513,586 patent/US7556795B2/en not_active Expired - Fee Related
- 2003-05-05 JP JP2004500926A patent/JP4885448B2/en not_active Expired - Fee Related
- 2003-05-05 CN CNB03812954XA patent/CN100471523C/en not_active Expired - Fee Related
- 2003-05-05 CA CA2485339A patent/CA2485339C/en not_active Expired - Fee Related
- 2003-05-05 WO PCT/US2003/013936 patent/WO2003092743A1/en active Application Filing
- 2003-05-05 AU AU2003239351A patent/AU2003239351B2/en not_active Ceased
- 2003-05-05 EP EP03733935A patent/EP1503804A4/en not_active Withdrawn
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103435684A (en) * | 2013-09-23 | 2013-12-11 | 武汉工程大学 | 18F-fluorine labeling pentapeptide complex and synthetic method thereof |
| CN103467504A (en) * | 2013-09-23 | 2013-12-25 | 武汉工程大学 | 18F-fluorine labeled porphyrin-isoindoline free radical complex and synthesis method thereof |
| CN103435684B (en) * | 2013-09-23 | 2015-10-28 | 武汉工程大学 | 18f-fluorine mark pentapeptide title complex and synthetic method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100471523C (en) | 2009-03-25 |
| AU2003239351A1 (en) | 2003-11-17 |
| WO2003092743A9 (en) | 2004-04-01 |
| JP2005526116A (en) | 2005-09-02 |
| AU2003239351B2 (en) | 2008-03-13 |
| US7556795B2 (en) | 2009-07-07 |
| CA2485339C (en) | 2012-02-14 |
| US20060034760A1 (en) | 2006-02-16 |
| WO2003092743A1 (en) | 2003-11-13 |
| EP1503804A1 (en) | 2005-02-09 |
| EP1503804A4 (en) | 2009-03-18 |
| CA2485339A1 (en) | 2003-11-13 |
| JP4885448B2 (en) | 2012-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1137136C (en) | Targeted cytotoxic anthracycline analogs | |
| CN1658907A (en) | Radiopharmaceutical formulations | |
| CN1055700C (en) | Therapeutic peptide derivatives | |
| CN1087631C (en) | Radiolabeled peptides for diagnosis and therapy | |
| CN1080127C (en) | Ternary radiopharmaceutical complexes | |
| CN1078480C (en) | Somatostatin binding peptide-metal chelate conjugates | |
| CN1156492C (en) | Somatostatin peptides | |
| US7226577B2 (en) | Gastrin releasing peptide compounds | |
| CN1093424C (en) | Monoamine, diamide, thiol-containingmetal chelating agents | |
| CN1622830A (en) | Peptide-based compounds | |
| CN1822861A (en) | Stable radiopharmaceutical compositions and methods for preparation | |
| CN1527727A (en) | Improved chelator conjugates | |
| CN1192733A (en) | Stable reagent for prepn. of radiopharmaceuticals | |
| CN1129224A (en) | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use | |
| CN1503680A (en) | Ascorbic a cid analogs for metalloradiopharmaceuticals | |
| CN1120437A (en) | Boronic acid, adducts of rhenium dioxime and techmetium-99M dioxime complexes containing a biochemically active group | |
| CN1295578A (en) | Pharmaceuticals for imaging of angiogenic disorders | |
| CN1929857A (en) | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof | |
| CN103533963A (en) | HER2 binding peptides labeled with aluminium-[18] fluoride complexed by nota | |
| JP2002506424A (en) | Gastrin receptor-affinity peptide conjugate | |
| CN103402550A (en) | HER2 binding peptides labelled with a 18F - containing organosilicon compound | |
| CN101076357A (en) | Enzyme inhibitor imaging agents | |
| CN1852742A (en) | Somatostatin analogs with inhibitory activity to growth hormone release | |
| CN1708322A (en) | Conjugates of TC complexes and targeting moieties and their use in MRI diagnostic | |
| CN1220702C (en) | Insulinotropic peptide and its use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090325 Termination date: 20130505 |